Volume Alert - GILD 106.94 Gilead Sciences $GILD Hit a high today of 108.45 Closing the day 11/06/14 at 106.94 +0.89 +0.84% With a day low of 106.10 and a total volume of 13,506,440.
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Final Glance: Biotechnology companies
AP - Thu Nov 06, 6:13PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 106.94 (+0.89), AMGN: 160.35 (+1.41), CELG: 107.14 (+1.99)
Midday Glance: Biotechnology companies
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 106.94 (+0.89), AMGN: 160.35 (+1.41), CELG: 107.14 (+1.99)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 43.69 (+0.03), GILD: 106.94 (+0.89), ABBV: 62.71 (+0.17)
Early Glance: Biotechnology companies
AP - Thu Nov 06, 9:51AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 106.94 (+0.89), AMGN: 160.35 (+1.41), CELG: 107.14 (+1.99)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 106.94 (+0.89), ACHN: 10.26 (+0.11)
Critical Alerts For Delta Airlines, ConocoPhillips, Qualcomm, Kinder Morgan and Gilead Sciences Released By InvestorsObserver
PR Newswire - Thu Nov 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for DAL, COP, QCOM, KMI and GILD.
KMI: 38.53 (+0.43), GILD: 106.94 (+0.89), DAL: 42.90 (+1.03), QCOM: 70.58 (-6.62), COP: 71.32 (+1.44)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 106.94 (+0.89), PFE: 30.04 (unch), LH: 102.93 (+0.72), ABBV: 62.71 (+0.17), CVD: 101.10 (+0.15)
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV
Business Wire - Thu Nov 06, 7:31AM CST
--- First of Several TAF-Based Single Tablet Regimens Being Evaluated by Gilead -
GILD: 106.94 (+0.89)
OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection
PR Newswire - Wed Nov 05, 3:48PM CST
Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved OLYSIO® (simeprevir), a hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen. Sofosbuvir is an HCV nucleotide analog NS5B polymerase inhibitor developed by Gilead Sciences, Inc.
GILD: 106.94 (+0.89)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 3.35%
Comtex SmarTrend(R) - Wed Nov 05, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.75 to a high of $110.91. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $108.81 on volume of 15.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 106.94 (+0.89)
After Yesterday's Decline of 3.35%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Wed Nov 05, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.75 to a high of $110.91. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $108.81 on volume of 15.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 106.94 (+0.89)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 94.55 (+1.05), VRTX: 117.29 (+5.70), BMRN: 84.03 (+2.06), GILD: 106.94 (+0.89), ALXN: 193.14 (+3.25)
Earnings Forecast Buzz for Alibaba, GT Advanced Technologies, GoPro, Plug Power, Gilead Sciences, and American Realty Capital Properties
PR Newswire - Tue Nov 04, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), GT Advanced Technologies (OTCMKTS:GTATQ), GoPro (NASDAQ:GPRO), Plug Power (NASDAQ
LUG), Gilead Sciences (NASDAQ:GILD), and American Realty Capital Properties (NASDAQ:ARCP).
GPRO: 78.76 (+2.87), GILD: 106.94 (+0.89), PLUG: 5.12 (+0.16), ARCP: 8.64 (-0.07), BABA: 111.57 (+2.90)
Life-Science New Build Report: 200 New North American Sites in Planning Represent Potential $15 Billion Investment, an Industrial Info News Alert
Marketwired - Tue Nov 04, 5:16AM CST
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- It has become difficult, if not nearly impossible, for many of America's politicians to find common ground at any level. The outlier in this case appears to be the courting and landing of new life science industry facilities. In North America alone, there are currently 200 reported new-facility builds on the books, representing a total investment value of $15.4 billion.
GILD: 106.94 (+0.89), BAX: 71.60 (+0.70)
Gilead Sciences Once Again Tops the List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking
Marketwired - Tue Nov 04, 5:15AM CST
Gilead Sciences claims seven top-ranked positions in the 2015 All-America Executive Team survey, Institutional Investor's annual poll of investors and sell-side analysts regarding America's top executives, IR professionals and IR programs.
GILD: 106.94 (+0.89)
'Fast Money' Recap: Lower Oil Prices a Warning Sign for Stocks
at The Street - Tue Nov 04, 4:00AM CST
The trading panel discussed financial, chipmaker and pharmaceutical companies.
YHOO: 47.93 (+0.47), GPRO: 78.76 (+2.87), GILD: 106.94 (+0.89), XOP: 59.25 (+0.53), UTX: 108.58 (+0.65), SUNE: 18.37 (-0.51), FFIV: 125.21 (-0.21), MCD: 94.66 (+0.02), SLV: 14.82 (+0.16), TLT: 118.39 (-0.77), NVDA: 20.22 (+0.09), BABA: 111.57 (+2.90)
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Final Glance: Biotechnology companies
AP - Thu Nov 06, 6:13PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 106.94 (+0.89), AMGN: 160.35 (+1.41), CELG: 107.14 (+1.99)
Midday Glance: Biotechnology companies
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 106.94 (+0.89), AMGN: 160.35 (+1.41), CELG: 107.14 (+1.99)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 43.69 (+0.03), GILD: 106.94 (+0.89), ABBV: 62.71 (+0.17)
Early Glance: Biotechnology companies
AP - Thu Nov 06, 9:51AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 106.94 (+0.89), AMGN: 160.35 (+1.41), CELG: 107.14 (+1.99)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 106.94 (+0.89), ACHN: 10.26 (+0.11)
Critical Alerts For Delta Airlines, ConocoPhillips, Qualcomm, Kinder Morgan and Gilead Sciences Released By InvestorsObserver
PR Newswire - Thu Nov 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for DAL, COP, QCOM, KMI and GILD.
KMI: 38.53 (+0.43), GILD: 106.94 (+0.89), DAL: 42.90 (+1.03), QCOM: 70.58 (-6.62), COP: 71.32 (+1.44)
Quarterly Financial Results, Acquisition Agreement, and Accelerated Drug Approval - Research Reports on Gilead, Covance, Laboratory Corp., Pfizer and AbbVie
PR Newswire - Thu Nov 06, 8:30AM CST
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
GILD: 106.94 (+0.89), PFE: 30.04 (unch), LH: 102.93 (+0.72), ABBV: 62.71 (+0.17), CVD: 101.10 (+0.15)
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV
Business Wire - Thu Nov 06, 7:31AM CST
--- First of Several TAF-Based Single Tablet Regimens Being Evaluated by Gilead -
GILD: 106.94 (+0.89)
OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection
PR Newswire - Wed Nov 05, 3:48PM CST
Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved OLYSIO® (simeprevir), a hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen. Sofosbuvir is an HCV nucleotide analog NS5B polymerase inhibitor developed by Gilead Sciences, Inc.
GILD: 106.94 (+0.89)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 3.35%
Comtex SmarTrend(R) - Wed Nov 05, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.75 to a high of $110.91. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $108.81 on volume of 15.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 106.94 (+0.89)
After Yesterday's Decline of 3.35%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Wed Nov 05, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.75 to a high of $110.91. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $108.81 on volume of 15.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 106.94 (+0.89)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 94.55 (+1.05), VRTX: 117.29 (+5.70), BMRN: 84.03 (+2.06), GILD: 106.94 (+0.89), ALXN: 193.14 (+3.25)
Earnings Forecast Buzz for Alibaba, GT Advanced Technologies, GoPro, Plug Power, Gilead Sciences, and American Realty Capital Properties
PR Newswire - Tue Nov 04, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), GT Advanced Technologies (OTCMKTS:GTATQ), GoPro (NASDAQ:GPRO), Plug Power (NASDAQ
LUG), Gilead Sciences (NASDAQ:GILD), and American Realty Capital Properties (NASDAQ:ARCP). GPRO: 78.76 (+2.87), GILD: 106.94 (+0.89), PLUG: 5.12 (+0.16), ARCP: 8.64 (-0.07), BABA: 111.57 (+2.90)
Life-Science New Build Report: 200 New North American Sites in Planning Represent Potential $15 Billion Investment, an Industrial Info News Alert
Marketwired - Tue Nov 04, 5:16AM CST
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- It has become difficult, if not nearly impossible, for many of America's politicians to find common ground at any level. The outlier in this case appears to be the courting and landing of new life science industry facilities. In North America alone, there are currently 200 reported new-facility builds on the books, representing a total investment value of $15.4 billion.
GILD: 106.94 (+0.89), BAX: 71.60 (+0.70)
Gilead Sciences Once Again Tops the List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking
Marketwired - Tue Nov 04, 5:15AM CST
Gilead Sciences claims seven top-ranked positions in the 2015 All-America Executive Team survey, Institutional Investor's annual poll of investors and sell-side analysts regarding America's top executives, IR professionals and IR programs.
GILD: 106.94 (+0.89)
'Fast Money' Recap: Lower Oil Prices a Warning Sign for Stocks
at The Street - Tue Nov 04, 4:00AM CST
The trading panel discussed financial, chipmaker and pharmaceutical companies.
YHOO: 47.93 (+0.47), GPRO: 78.76 (+2.87), GILD: 106.94 (+0.89), XOP: 59.25 (+0.53), UTX: 108.58 (+0.65), SUNE: 18.37 (-0.51), FFIV: 125.21 (-0.21), MCD: 94.66 (+0.02), SLV: 14.82 (+0.16), TLT: 118.39 (-0.77), NVDA: 20.22 (+0.09), BABA: 111.57 (+2.90)
